Roivant Sciences LTD Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Roivant Sciences Ltd. increased its beneficial ownership in Immunovant, Inc. to 55.9% by acquiring 16.67 million shares in a recent public offering.
NASDAQ
SCHEDULE 13D/A: Immunovant Appoints Roivant Executive Eric Venker as New CEO in Latest Schedule 13D/A Amendment
Immunovant, Inc. announced the appointment of Eric Venker, M.D., President and Chief Operating Officer of Roivant Sciences, Inc., as its new Chief Executive Officer, effective April 21, 2025, as detailed in an amended Schedule 13D filing by major shareholder Roivant Sciences Ltd.
NASDAQ
SCHEDULE 13D/A: Roivant Sciences Orchestrates Major Board Overhaul at Arbutus Biopharma, Appointing New CEO and Directors
Roivant Sciences Ltd., a significant shareholder in Arbutus Biopharma Corp, has successfully orchestrated a complete change in Arbutus's Board of Directors, reducing its size and appointing new leadership, including a new CEO.
NASDAQ
SCHEDULE 13D/A: Roivant Sciences Amends Arbutus Biopharma Stake, Signals Potential Board and Management Changes
Roivant Sciences Ltd. has filed an Amendment No. 12 to its Schedule 13D, reaffirming its 20.5% beneficial ownership in Arbutus Biopharma Corp. and indicating potential near-term changes to the Issuer's board of directors and management.
NASDAQ
SCHEDULE 13D/A: Roivant Sciences Boosts Immunovant Stake with $337 Million Private Placement for Pipeline Advancement
Roivant Sciences Ltd. has increased its beneficial ownership in Immunovant, Inc. to 56.9% through a $337 million private placement, providing capital for Immunovant's development pipeline and general corporate purposes.